Drug Profile
Research programme: HDAC1/2 inhibitors - Regenacy Pharmaceuticals
Alternative Names: ACY 957; ACY-1035; RCY-1305Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Acetylon Pharmaceuticals
- Developer Regenacy Pharmaceuticals
- Class Small molecules
- Mechanism of Action Erythropoiesis stimulants; Fetal haemoglobin stimulants; HDAC1 protein inhibitors; HDAC2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Beta-thalassaemia; Leukaemia; Psychiatric disorders; Sickle cell anaemia
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)
- 28 Mar 2022 No recent reports of development identified for preclinical development in Beta-thalassaemia in USA (PO)
- 28 Mar 2022 No recent reports of development identified for preclinical development in Leukaemia in USA (PO)